Immunization with Hepatitis C Virus-like Particles Induces Humoral and Cellular Immune Responses in Nonhuman Primates

Overview

Journal J Virol

Publisher American Society for Microbiology

Date 2004 Jun 15

PMID 15194776

Citations 42

Authors

Sook-Hyang Jeong

Ming Qiao

Michelina Nascimbeni

Zongyi Hu

Barbara Rehermann

Krishna Murthy

T Jake Liang

Affiliations

Soon will be listed here.

Abstract

We have previously reported the production of hepatitis C virus-like particles (HCV-LP) using a recombinant baculovirus containing the cDNA of the HCV structural proteins (core, E1, and E2). These particles resemble the putative HCV virions and are capable of inducing strong and broad humoral and cellular immune responses in mice. Here we present evidence on the immunogenicity of HCV-LP and the effects of novel adjuvant systems in a nonhuman primate model, the baboon. Three groups of four baboons were immunized with HCV-LP, HCV-LP and adjuvant AS01B (monophosphoryl lipid A and QS21), or HCV-LP and the combination of AS01B and CpG oligodeoxynucleotides 10105. After four immunizations over an 8-month period, all animals developed HCV-specific humoral and cellular immune responses including antibodies to HCV structural proteins and gamma interferon(+) (IFN-gamma(+))CD4(+) and IFN-gamma(+)CD8(+) T-cell responses. The immunogenicity of HCV-LP was only marginally enhanced by the use of adjuvants. The overall HCV-specific immune responses were broad and long lasting. Our results suggest that HCV-LP is a potent immunogen to induce HCV-specific humoral and cellular immune responses in primates and may be a promising approach to develop novel preventive and therapeutic modalities.

Citing Articles

Recent Advances in Antiviral Drug Delivery Strategies.

Rana D, Prajapati A, Karunakaran B, Vora L, Benival D, Jindal A AAPS PharmSciTech. 2025; 26(3):73.

PMID: 40038154 DOI: 10.1208/s12249-025-03053-3.

Virus-Mimicking Polymer Nanocomplexes Co-Assembling HCV E1E2 and Core Proteins with TLR 7/8 Agonist-Synthesis, Characterization, and In Vivo Activity.

Fuerst T, Marin A, Jeong S, Kulakova L, Hlushko R, Gorga K J Funct Biomater. 2025; 16(1).

PMID: 39852590 PMC: 11766188. DOI: 10.3390/jfb16010034.

[Development approaches for vaccines against hepatitis C virus infections].

Bankwitz D, Krey T, Pietschmann T Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2022; 65(2):183-191.

PMID: 35015104 PMC: 8749110. DOI: 10.1007/s00103-021-03477-9.

Viral hepatitis update: Progress and perspectives.

Pisano M, Giadans C, Flichman D, Re V, Preciado M, Valva P World J Gastroenterol. 2021; 27(26):4018-4044.

PMID: 34326611 PMC: 8311538. DOI: 10.3748/wjg.v27.i26.4018.

Immunopotentiating and Delivery Systems for HCV Vaccines.

Andrianov A, Fuerst T Viruses. 2021; 13(6).

PMID: 34070543 PMC: 8227888. DOI: 10.3390/v13060981.

References

Paliard X, Liu Y, Wagner R, Wolf H, Baenziger J, Walker C . Priming of strong, broad, and long-lived HIV type 1 p55gag-specific CD8+ cytotoxic T cells after administration of a virus-like particle vaccine in rhesus macaques. AIDS Res Hum Retroviruses. 2000; 16(3):273-82. DOI: 10.1089/088922200309368. View

Weeratna R, McCluskie M, Xu Y, Davis H . CpG DNA induces stronger immune responses with less toxicity than other adjuvants. Vaccine. 2000; 18(17):1755-62. DOI: 10.1016/s0264-410x(99)00526-5. View

Lechner F, Wong D, Dunbar P, Chapman R, Chung R, Dohrenwend P . Analysis of successful immune responses in persons infected with hepatitis C virus. J Exp Med. 2000; 191(9):1499-512. PMC: 2213430. DOI: 10.1084/jem.191.9.1499. View

Takaki A, Wiese M, Maertens G, Depla E, Seifert U, Liebetrau A . Cellular immune responses persist and humoral responses decrease two decades after recovery from a single-source outbreak of hepatitis C. Nat Med. 2000; 6(5):578-82. DOI: 10.1038/75063. View

Forns X, Payette P, Ma X, Satterfield W, Eder G, MUSHAHWAR I . Vaccination of chimpanzees with plasmid DNA encoding the hepatitis C virus (HCV) envelope E2 protein modified the infection after challenge with homologous monoclonal HCV. Hepatology. 2000; 32(3):618-25. DOI: 10.1053/jhep.2000.9877. View

Chang K, Thimme R, Melpolder J, Oldach D, Pemberton J, McHutchison J . Differential CD4(+) and CD8(+) T-cell responsiveness in hepatitis C virus infection. Hepatology. 2000; 33(1):267-76. DOI: 10.1053/jhep.2001.21162. View

Gruener N, Lechner F, Jung M, Diepolder H, Gerlach T, Lauer G . Sustained dysfunction of antiviral CD8+ T lymphocytes after infection with hepatitis C virus. J Virol. 2001; 75(12):5550-8. PMC: 114267. DOI: 10.1128/JVI.75.12.5550-5558.2001. View

Bassett S, Guerra B, Brasky K, Miskovsky E, Houghton M, Klimpel G . Protective immune response to hepatitis C virus in chimpanzees rechallenged following clearance of primary infection. Hepatology. 2001; 33(6):1479-87. DOI: 10.1053/jhep.2001.24371. View

Lanford R, Bigger C, Bassett S, Klimpel G . The chimpanzee model of hepatitis C virus infections. ILAR J. 2001; 42(2):117-26. DOI: 10.1093/ilar.42.2.117. View

10.

Payette P, Mancini M, Tiollais P, Davis H, Michel M . CpG oligodeoxynucleotides with hepatitis B surface antigen (HBsAg) for vaccination in HBsAg-transgenic mice. J Virol. 2001; 75(14):6482-91. PMC: 114371. DOI: 10.1128/JVI.75.14.6482-6491.2001. View

11.

Lauer G, Walker B . Hepatitis C virus infection. N Engl J Med. 2001; 345(1):41-52. DOI: 10.1056/NEJM200107053450107. View

12.

Lechmann M, Murata K, Satoi J, Vergalla J, Baumert T, Liang T . Hepatitis C virus-like particles induce virus-specific humoral and cellular immune responses in mice. Hepatology. 2001; 34(2):417-23. DOI: 10.1053/jhep.2001.26523. View

13.

Mondelli M, Cerino A, Segagni L, Meola A, Cividini A, Silini E . Hypervariable region 1 of hepatitis C virus: immunological decoy or biologically relevant domain?. Antiviral Res. 2001; 52(2):153-9. DOI: 10.1016/s0166-3542(01)00180-2. View

14.

Thimme R, Oldach D, Chang K, Steiger C, Ray S, Chisari F . Determinants of viral clearance and persistence during acute hepatitis C virus infection. J Exp Med. 2001; 194(10):1395-406. PMC: 2193681. DOI: 10.1084/jem.194.10.1395. View

15.

Rosen H, Miner C, Sasaki A, Lewinsohn D, Conrad A, Bakke A . Frequencies of HCV-specific effector CD4+ T cells by flow cytometry: correlation with clinical disease stages. Hepatology. 2002; 35(1):190-8. DOI: 10.1053/jhep.2002.30293. View

16.

Prince A . Perspectives on prophylactic and therapeutic immunization against hepatitis B and C viruses. Transfus Clin Biol. 2002; 8(6):467-70. DOI: 10.1016/s1246-7820(01)00200-2. View

17.

Sithebe N, Kew M, Mphahlele M, Paterson A, Lecatsas G, Kramvis A . Lack of susceptibility of Chacma baboons (Papio ursinus orientalis) to hepatitis C virus infection. J Med Virol. 2002; 66(4):468-71. DOI: 10.1002/jmv.2167. View

18.

Triyatni M, Vergalla J, Davis A, Hadlock K, Foung S, Liang T . Structural features of envelope proteins on hepatitis C virus-like particles as determined by anti-envelope monoclonal antibodies and CD81 binding. Virology. 2002; 298(1):124-32. DOI: 10.1006/viro.2002.1463. View

19.

Wedemeyer H, He X, Nascimbeni M, Davis A, Greenberg H, Hoofnagle J . Impaired effector function of hepatitis C virus-specific CD8+ T cells in chronic hepatitis C virus infection. J Immunol. 2002; 169(6):3447-58. DOI: 10.4049/jimmunol.169.6.3447. View

20.

Qiao M, Murata K, Davis A, Jeong S, Liang T . Hepatitis C virus-like particles combined with novel adjuvant systems enhance virus-specific immune responses. Hepatology. 2002; 37(1):52-9. DOI: 10.1053/jhep.2003.50000. View